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Obsessive–compulsive disorderThe ﬂy-catching syndrome (FCS) is a rare canine condition of sudden, occasional, or constant episodes of biting
the air. It may be accompanied by jumping, licking, and swallowing. The etiology of FCS is unknown and contro-
versial. Various explanations for its occurrence have included epileptoid disorders such as visual cortex epilepti-
form disturbances and simple and complex partial seizures as well as compulsive disorders, hallucinatory
behavior, and stereotypy. A retrospective multicenter analysis of 24 dogs with clinical symptoms of FCS is pre-
sented. Clinical signs at the time of presentation, the mean age at onset of the disease, the response to treatment,
and the clinical outcome were recorded and analyzed in all patients. All dogs underwent clinical, neurological,
and otoscopic examinations. Complete blood cell counts (CBCs) and serum chemistry panels were obtained
fromeachdog. Diagnostic testing includedMRI and EEGexaminations in 21 cases, BAER in 19 cases, andCSF anal-
ysis in 20 cases. The EEG revealed spike activity in 8 (38%) of the 21 cases, 7 of which had activity in the occipital
lobes. The brainstem auditory evoked response (BAER) revealed three cases of bilateral deafness. The MRI re-
vealed six cases of Chiari malformation (CM), one case of syringohydromyelia (SM), and one case of a falx cerebri
meningioma. The dogs were divided into groups according to their treatment protocol. Group A included dogs
treated with phenobarbital (PB), and group B consisted of dogs treated with ﬂuoxetine (FLX). Thirty-six percent
of the dogs in group A responded to PB, while 100% of the dogs in group B responded to FLX. The results suggest
that FCS ismore responsive to FLX than PB. However, the etiology of this behavior remains unclear inmost cases.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The ﬂy-catching syndrome (FCS) is a rare canine condition of sud-
den, occasional, or constant episodes of biting the air. It may be accom-
panied by jumping, licking, and swallowing. In the literature, it is also
known as ﬂy-snapping, ﬂy-biting, ﬂy-chasing, or jaw-snapping [1–4].
There have been numerous suggestions as to the cause of this disorder,
including early development of vitreous opacity problems (synchysis
scintillans) [4], peripheral neuropathy [2], visual anomalies and hyper-
activity [5], and dietary allergy (meat) [6]. Recently, a gastroesophageal
reﬂux (GER) similar to human Sandifer syndrome has also been sug-
gested as a possible cause of the syndrome [7]. Currently, an epileptic
or behavioral nature of FCS is considered to be most likely. Epileptoidease with Clinic of Horses, Dogs
ersity of Environment and Life
.: +48 71 3205 363.
sek).
. This is an open access article underdisturbances leading to FCS have been reported to include epileptic dis-
charges of the visual cortex, and theymay result either from central ner-
vous system (CNS) disease or from idiopathic epilepsy (IE) [3,8–13]. The
FCS has also been cited to be a compulsive disorder, hallucinatory be-
havior, obsessive–compulsive disorder (OCD), stereotypy [1,9,14,15],
or dyskinesia as an extrapyramidal disorder [13]. The Cavalier King
Charles Spaniel (CKCS), Miniature Schnauzer (MS), and Greater Swiss
Mountain Dog (GSMD) have been described as being predisposed to
this condition [15], although many other dog breeds including the
Doberman Pinscher, Airedale Terrier, Miniature Poodle, German
Shorthaired Pointer, German Shepherd, Border Collie, Irish Setter, and
the English Setter have also been found to display FCS [6,11,15–18].
The frequency of the episodes ranged from 30 per hour to once a
week, and the age at onset ranged from 1 to 11 years [6,11,13,15,17,18].
Considering that FCS has been reported in the literature to have a va-
riety of etiologies, functional (EEG, BAER) as well as structural (MRI,
CSF) examinations should be considered when evaluating dogs with
suspected FCS. Electroencephalography (EEG) is a noninvasivethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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diagnostic tool to conﬁrm andmonitor epilepsy in humans, but its prac-
tical relevance in animals remains unclear [19]. To date, an EEG assess-
ment has not been carried out on a large group of animals with FCS.
While the ﬁndings of speciﬁc diagnostic testing can guide one's treat-
ment decisions, a patient's response to treatment can sometimes pro-
vide suggestive evidence of the etiology of a given behavior. Therefore,
a good response to antiepileptic drugs (AEDs) suggests a possible epi-
leptic origin. Given that antidepressant treatment (ADT) is considered
as the medication of choice in the treatment of canine OCD [20], a
good response of patients with FCS to ADT suggests that OCD may be
its underlying cause. Thepurpose of this studywas to retrospectively as-
sess dogs with FCS from three different veterinary neurological centers
by means of EEG, BAER, MRI, and CSF results. The dogs were also evalu-
ated in terms of clinical signs at the time of presentation, the mean age
at the disease onset, the response to treatment, and the clinical outcome
following treatment.
2. Materials and methods
2.1. Case selection
The study included archived cases of 24 dogs with a record of FCS
from three neurological centers collected between 2007 and 2012. All
cases were referred for a neurological consultation. Eight cases were di-
agnosed at the Department of Internal Diseases with a Clinic for Horses,
Dogs and Cats at the Faculty of VeterinaryMedicine of theWrocławUni-
versity of Environment and Life Science, Poland; 12 caseswere recorded
in the Referral Animal Neurology Hospital Aisti, Vantaa, Finland; and 4
cases were identiﬁed at the Department of Internal Disease, Small Ani-
mal Clinic of the University of Veterinary Medicine, Vienna, Austria.
Cases with a minimum of two recorded episodes of abnormal behavior,
such as jumping, catching and swallowing imaginary objects, licking,
and air snapping in a sudden, compulsive, episodic way corresponding
to FCS that also had a documented medical history, were included in
the study (case example: Videos 1 and 2). All dogs underwent clinical,
orthopedic, neurological, and otoscopic examinations performed by
certiﬁed neurologists (MW, SC, and AP). A CBC and serum chemistry
panel (including urea, creatinine, glucose, cholesterol, TT4, cTSH, Na,
K, Ca, Mg, GOT, GPT, CPK, albumin, total protein, preprandial and post-
prandial ammonia, and bile acids) were performed on the dogs.
Twenty-one dogs underwent MRI and interictal EEG examinations.
The brainstem auditory evoked response (BAER) was performed in 19
cases. Both electrodiagnostic examinations were performed under a
medetomidine (20 μg/kg IM) sedation protocol. A visual EEG analysis
was carried out to detect epileptiform activity in the formof paroxysmal
discharges. A cerebrospinal ﬂuid (CSF) cisternal puncture and analysis
were carried out in 20 cases. The CSF examination included a cell
count and Pandy's reaction, aswell as a total protein and albumin quan-
tiﬁcation. Dogs treated with phenobarbital (PB) received it at a dose of
2–3 mg/kg PO BID. The PB serum level was measured at least 3 weeks
after the initiation of therapy and varied between 23 and 32 μg/ml. Pa-
tients in group B received ﬂuoxetine at a dose of 1-mg/kg PO BID. The
therapeutic effect of antiepileptic (PB) and/or antidepressive treatment
(FLX) was recorded for each dog. This was calculated based on the fre-
quency of the FCS episodes reported by the owners. Therapy was con-
sidered to be effective when the ﬂy-catching (FC) episodes were
reduced by more than 50% within a three-month treatment period.
These dogs were deﬁned as “responders”. If an improvement was
noted, but the number of ﬂy-catching episodes remained greater than
50% of the initial number, treatment was considered unsatisfactory,
and dogs were deﬁned as “nonresponders”. The dose and frequency of
use of each drug were recorded in each case. For the purpose of this
study, patients were divided into three groups depending on the type
of therapy received: group A included dogs treated with PB; group B
contained dogs that received FLX; while group C consisted of dogsunder therapy different from that in groups A and B. Because of the
heterogeneity of treatment received by dogs in group C, only groups A
and B were compared statistically.
2.2. Statistical analysis
Data regarding the efﬁcacy of the therapywere analyzed statistically.
Because of the lack of uniform information about the clinical status of all
the animals during and after treatment in this multicenter study, binary
data were assessed, applying the chi-square test for differences among
more than two proportions (comparison of the response to treatment
and comparison of the occurrence of EDs between groups). The differ-
ence between the treatment results was considered statistically signiﬁ-
cant if p b 0.05.
2.3. Ethics committee approval
The study protocol was approved by the Regional Ethics Committees
for Animal Research (permit number 106/2010).
3. Results
The study included 24 cases, of which 10were CKCS and the remain-
ingdogswere of different breeds (American Staffordshire Terrier, Boxer,
Cocker Spaniel, Dachshund, Dalmatian, French Bulldog, German Shep-
herd, German Shorthaired Pointer, Jack Russell Terrier, Miniature
Schnauzer, Portuguese Sheepdog, Pyrenees Dog, West Highland White
Terrier [WHWT], and mixed breed). The age at onset of the symptoms
was between ﬁve months and 12 years of age (median: 24 months,
mean: 35 months). Seventeen males and seven females comprised the
study group. In 4 dogs, the owners reported additional behavioral dis-
turbances including excessive licking in the air (one WHWT); face,
neck, and ear scratching; paw licking; excessive tail-chasing; head shak-
ing; and hind-limb biting (three CKCSs). Two dogs (CKCS) had a history
of external otitis, and one had a history of food allergy. The clinical, or-
thopedic, and otoscopic examinations did not reveal abnormalities in
any of the dogs. The neurological examination revealed a slightly bilat-
erally reduced menace response in ﬁve cases (JRT, schnauzer, 3 CKCSs)
and a slight head tilt to the right (one American Staffordshire Terrier).
No abnormalities were recorded in the CBC and serum chemistry anal-
ysis. The BAER examination revealed two cases of bilateral sensorineu-
ral deafness (American Staffordshire Terrier and Dachshund) and one
case of bilateral age-related deafness (presbycusis in a 12-year-old Ger-
man Shepherd [GSH]). Of the 21 dogs that underwent MRI of the head,
two cases (Boxer and CKCS) had a mild lateral ventricular asymmetry,
six CKCSs (Chiari malformation; CM) had mild occipital bone hypopla-
sia, one of the CKCSs had mild syringohydromyelia (SM), and the GSH
had a small meningioma (3/5 mm in diameter) of the right falx cerebri.
In all dogs, the CSF examination did not reveal any pathological abnor-
malities (cell count b 5 μl, TP b 25 μg/dl). The summary of the history,
examination results, initial diagnosis, and treatment results of all ana-
lyzed patients is presented in Table 1.
Group A (n = 11) consisted of cases initially treated with PB. Four
(36%) dogs responded to treatment, whereas seven (64%) dogs were
classiﬁed as nonresponders. Group B (n = 11) included dogs initially
treated with FLX, two cases from group A that did not respond to PB,
who subsequently underwent FLX therapy, and one case that was ini-
tially treated with gabapentin (GB) that later received GB and FLX and
eventually received solely FLX. In this group, 11 (100%) dogs were re-
sponders. There was a statistically signiﬁcant difference in the response
of the dogs to treatment between groups A and B (p b 0.05).
Group C (n= 6) consisted of patients treated with a combined thera-
py that could not be compared due to the heterogeneity of treatment. It
included two dogs that were responders to a combined PB, FLX, and
CAR treatment (cases 22 and 10), one GB and FLX-responder (case 18),
Table 1
Summary of the history, MRI, EEG examinations, and treatment.
Case
number
Breed Age at
onset
(m)
Gender History MRI EEG End diagnosis Treatment summary Treatment end effect Treatment
group
1 Boxer 48 M FCS and focal and complex
partial seizures
Asymmetric lateral
ventricles (L N R)
Spikes T and O IE PB PB responder A
14 Dalmatian 42 M FCS and seizures Normal Normal IE PB PB responder A
9 Pyrenees dog 108 F spayed FCS Normal Spikes bilat. O IE PB PB responder A
19 French
Bulldog
55 M FCS Normal Spikes bilat. F IE PB PB responder A
15 Schnauzer 16 F FCS Normal Spikes Rt. O and
P
IE PB PB nonresponder A
13 JRT 24 M FCS Normal Spikes bilat. O IE and OCD PB PB nonresponder A
21 CKCS 12 M FCS n/a Normal OCD PB PB nonresponder A
7 Cocker
Spaniel
12 M FCS Normal Normal OCD PB — no effect, then FLX PB nonresponder, FLX
responder
A and B
23 Mixed breed 10 F FCS Normal n/a OCD PB — no effect, then FLX PB nonresponder, FLX
responder
A and B
3 CKCS 12 F FCS CM, mild ventricular
enlargement
LVHA OCD FLX FLX responder B
4 CKCS 41 M FCS, focal seizure, history of
otitis externa
Slight CM Normal Mild CM, OCD FLX FLX responder B
11 CKCS 24 M FCS Normal Spikes bilat. O OCD FLX FLX responder B
16 CKCS 71 M Episodic FC, neck and ears
scratching, and paw biting
Asymmetry of lateral
ventricles with right
one enlarged, CM
Spikes Lt. Ct, O OCD FLX FLX responder B
17 CKCS 11 M Excessive tail-chasing, FC and
scratching the neck, and head
shaking
Mild CM Normal Mild CM, OCD FLX FLX responder B
20 Portuguese
Sheepdog
5 M FCS after playing or when
calm, increase by stress
Normal Normal OCD FLX FLX responder B
24 CKCS 12 M FCS n/a n/a OCD FLX FLX responder B
8 WHWT 10 F FCS, excessive licking n/a Normal OCD FLX FLX responder B
5 CKCS 28 M FCS, food allergy, and otitis
externa
CM and slight SM Normal CM + SM, OCD GB — no effect, then GB +
FLX, improved, after 5 m only
on FLX — improved
FLX responder B
18 CKCS 7 M FCS, progressive behavior
abnormality, scratch on the
face, hind-limb biting
Mild CM and SM Normal SM and
hypersensitivity, OCD
GB — no effect, then GB +
FLX
GB + FLX responder C
12 GSH 144 F spayed Deafness, FCS Meningioma, Rt. falx
cerebri side,
approximately3/5 mm
Normal OCD,
meningioma-induced,
presbycusis
DZ — no effect, then DZ +
FLX
DZ + FLX responder C
22 German
Shorthaired
Pointer
12 M FCS Normal n/a OCD PB — no effect, then PB +
FLX + CAR
PB nonresponder, PB +
FLX + CAR responder
A and C
10 CKCS 48 M FCS Normal Spikes bilat. O OCD CLOMI — no effect, then PB +
FLX+ CAR
PB + FLX + CAR
responder
C
2 American
StaffordShire
Terrier
36 M FCS Normal Normal Deafness, OCD PB, no effect, then PB +
FLX — no effect
PB nonresponder, PB +
FLX nonresponder
A and C
6 Dachshund 60 F spayed FCS Normal Normal Deafness, tinnitus,
and OCD
AMI — no effect, then FLX +
GB
GB + FLX nonresponder C
Legend (alphabetically): A: group A under PB treatment; AMI: amitriptyline; B: group B under FLX treatment; bilat.: bilaterally; C: group C under PB and FLX treatment; Ct: central lobe; CAR: carbamazepine; CKCS: Cavalier King Charles Spaniel;
CLOMI: clomipramine; CM: Chiari malformation; DZ: diazepam; EEG: electroencephalography; F: frontal lobe; FCS: ﬂy-catching syndrome; FLX: ﬂuoxetine; GB: gabapentin; GSH: German Shepherd; IE: idiopathic epilepsy; JRT: Jack Russell Terrier;
Lt.: left; m:months, LVHA: low-voltage high amplitude; MRI: magnetic resonance imaging; n/a; not acquired; O: occipital lobe; OCD: obsessive–compulsive disorder; PB: phenobarbital; Rt.: right; SM: syringohydromyelia; T: temporal lobe;WHWT:
West Highland White Terrier.
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187M. Wrzosek et al. / Epilepsy & Behavior 53 (2015) 184–189oneDZ and FLX-responder (case 12), and two PB and FLX-nonresponders
that also did not respond to GB and FLX (cases 2 and 6).
In group A, two dogs had a history of seizures (focal, complex par-
tial, and generalized tonic–clonic) in addition to the FC symptoms. In
ﬁve cases, the EEG examination revealed spike activity in the
temporooccipital, occipital, and frontal derivations. None of the PB non-
responders from group A had a history of clinical seizures. In two of the
seven nonresponders, EEG revealed spikes (occipital and parietal
lobes). One PB nonresponder (case 2)was diagnosedwith bilateral sen-
sorineural deafness. TheMRI in group A did not reveal any clinically rel-
evant changes.
One dog in group B (9%) had signs of focal seizures (facial twitching)
aswell as FCS (case 4). The EEG revealed anomalies in the form of spikes
in 2 cases localized in the centrooccipital and occipital areas (Fig. 1),
while one dog had generalized low-valence high-arousal (LVHA) activ-
ity. All three cases that had abnormal EEG recordings were CKCS that
responded to FLX, two of which had CM and ventriculomegaly.
In group C, one dog (case 12) was diagnosed with a small meningi-
oma concomitantwith presbycusis. In this group, the BAER examination
revealed bilateral sensorineural deafness in both nonresponders (cases
2, 6). In group C, noneof thedogs showed clinical seizures. However, the
EEG examination revealed occipital spikes in case 10.
4. Discussion
Although theﬁrst reports ofﬂy-biting behavior appeared in 1962 [4],
FCS in dogs is still poorly understood, and its frequency is unknown. The
etiology of this behavior is controversial and has been reported as epi-
leptoid disorders of the visual cortex or simple and complex partial sei-
zures as well as compulsive disorders, hallucinatory behavior, and
stereotypy. On the onehand, there are cases reporting FC behavior com-
bined with evident epileptic seizures (e.g., generalized tonic–clinic sei-
zure [GTCS]) [10–12]. On the other hand, the literature describes dogs
exhibiting FCS, without evident epileptic seizures, with additional be-
havioral disturbances including licking of the paw and ﬂoor, running
into objects, lying in the yard and crying, eating mud, following theFig. 1. Electroencephalograph of a dog with clinical FCS. Monopolar montage: F3–X1, F4–X1, C3
tage: F3–C3, C3–T3, T3–O1, F4–C4, C4–T4, and T4–O2, (F, frontal; T, temporal; C, central; O, occ
ography (OV–X1). Bilateral spike activity is shown in the central area (arrows).owner, biting family members without any apparent reason, defecating
on the bed [2], or biting and sucking their hindlimbs and pelage [7]. In
our study of 24 dogs, only three dogs had evident focal and partial sei-
zures (cases 1 and 4) or GTSC (case 14) based on the owner's descrip-
tion of the episodes. Behavioral disturbances other than FC that were
observed in the dogs in this study included excessive paw licking and
biting (one WHWT), neck and ear scratching, hindlimb biting, and ex-
cessive tail-chasing (two CKCSs). These behaviors could not be clearly
classiﬁed as of epileptic — or OCD origin. In the CKCS, these behaviors
have very often been described as a clinical presentation of CM [15],
which was observed in a mild form in both CKCS dogs in this study.
In our group, the median age of FCS onset was 24 months. Overall
and Dunham reported that the mean age of OCD onset in dogs was
under 2 years of age [14]. Very commonly, this is also the age at onset
of seizures of epileptic origin [13,19]. Therefore, these data are not spe-
ciﬁc and should not be considered when differentiating between an
epileptic nature and OCD nature of the disorder.
The CKCS, MS, and GSMD are breeds reported to be predisposed to
FCS [17]. The present study included ten CKCSs and one MS. Of the
eight CKCSs that underwent MRI, two showed no abnormalities. This
supports the speculation that FC occurs in the CKCS because of general
breed-speciﬁc CNS structural anomalies and may be a part of the cere-
bral syndrome. A case report of a toy fox terrier with CM and FC symp-
toms that did not respond to PB may support the suspected correlation
between these two neurological conditions [8]. On the other hand, MS
and GSMD are breeds that do not have predispositions to intracranial
structural disorders but exhibit FC behavior. A correlation between
thrombocytopenia and macrothrombocytosis in the CKCS and the oc-
currence of FCS have also been suspected [21]. Secondary cerebral circu-
lation damage has also been suggested as a possible cause of this
behavior. Some reports present individual cases of FCS, while others
focus on describing this phenomenon as a manifestation of a given
CNSpathology [19]. The FCS combinedwith seizure activitywas also ob-
served in other cases of vascular pathology [22]. TheMRI analysis in the
present group did not reveal any vascular pathology, although MR se-
quences that reﬂect vascular pathology were not carried out in any of–X1, C4–X1, T3–X1, T4–X1, O1–X1, and O2–X1, reference (X1) at the vertex, bipolar mon-
ipital; odd numbers= left hemisphere; even numbers = right hemisphere), electrocardi-
188 M. Wrzosek et al. / Epilepsy & Behavior 53 (2015) 184–189the dogs. The MRI examination, which was carried out in 20 of the 24
dogs, revealed a small meningioma in one dog, CM in six dogs, and SM
in one dog. A neuropathological examination was not performed on
these dogs. Gross pathological changes of the CNS were excluded in
the remaining dogs.
Fly-biting stereotypy preceding a generalized tonic–clonic seizure
(GTCS), described in an intoxicated setter dog, resolved after treatment
of the intoxication [11]. In that case, an EEG revealed intermittent bursts
of EDs with clinically apparent facial motor activity. The FCS deﬁned as
partial motor seizures was described in two Irish setters with globoid
cell leukodystrophy [10]. Based on the aforestated cases, one should
take into consideration that epileptic facilitation may cause FCS and
that its etiology may vary.
Electroencephalography is a noninvasive functional evaluation of the
CNS [23,24] and may differentiate epilepsy from a nonepileptic disorder
such as behavioral or compulsive disorders. Although EEG has special di-
agnostic importance for epilepsy in humans, it has been relatively rarely
used for the differentiation of CNS diseases in veterinary medicine [19,
25–27]. The epileptiform discharges (EDs) recorded on EEG in dogs in-
clude the following: spikes, sharp waves, spike-slow waves, polyspikes,
and polysharp waves [28,29]. In the current study, epileptic discharges
(EDs) of spikes were detected in 8/21 (38%) cases, though recordings
were not obtainedduringﬂy-catching episodes.Nonepileptic, generalized
low-valence high-arousal (LVHA) activity, which we consider to be
caused by concomitant ventriculomegaly, was found in one CKCS. There
are very few reports of EEG ﬁndings in dogs displaying FCS. The EEG of
one of the eight dogs with FCS described in 1979 revealed no particular
changes [2]. In our group, EDs were most commonly (n = 7) localized
in the occipital lobes. This may support the theory that temporooccipital
partial seizures or epileptiform hallucinations do appear in dogs
exhibiting FC. The EEG activity found in 38% of the dogs in this study in-
cluded focal spikes. The presence of focal spikes can be seen in healthy
human persons (0.5–4%) [23]. In epileptic dogs, EEG detectability of EDs
varies from 12.5% to 100%, although it has not been reported in healthy
dogs [28,30]. In our study, three of the four PB responders and two
(18%) of the eleven FLX responders displayed spikes in the EEG. One
dog that did not have any EEG abnormalities was diagnosed with FCS
combined with GTCS (case 14). The number of dogs in this study is too
small for the presented data to have deﬁnitive statistical values. However,
these ﬁndings may be noted for future research.
Studies reporting dogs with FCS episodes that precede a GTCS suggest
this behavior to have an epileptic nature [11]. However, simple partial or
complex partial seizures may be misinterpreted as OCD. During such an
episode, the animal does not lose consciousness, and focal motor or sen-
sory signs are observed [9,31]. The epileptic nature of FCS has also been
explained as hallucinatory behaviors due to visual cortex disorders [13].
Since sensory disturbances cannot be truly identiﬁed in animals, a differ-
entiation between the epileptic and the OCD nature of FCS is difﬁcult to
establish. The exact description of the animal's response to its surround-
ing environment during an FCS episode may aid in distinguishing the
two conditions. Obsessive–compulsive disorder can usually bemodulated
by distracting the animal using external stimuli (example Video 2), and a
postictal period is not observed [13]. Exceptions to this generalization are
possible. Most of the reported animals in this studywere found to exhibit
FCS behavior while being fully alert, which is characteristic of OCD, but
does not exclude partial seizures [13]. Dogs in this study appeared to re-
spond to the FLX protocol better than dogs receiving PB treatment
(100% in group B vs. 36% in groupA). Experimentalmedicine has revealed
a strong effect of antidepressants on the frequency of seizures [32,33].
However, we suggest considering the OCD nature of the FC behavior in
cases with no seizure activity.
The BAER examination revealed sensorineural deafness in two cases
and age-related deafness in one case (presbycusis). Both dogs with sen-
sorineural deafness did not respond to either chemical or behavioral
forms of treatment and were eventually euthanized by the owners
due to excessive FC symptoms. These dogs were found to have themost severe symptoms of all the dogs included in this study. The
comorbidity of OCD and deafness has been described in a population
of human patients with tinnitus [34]. Although we can only speculate
whether their FC behavior was a form of OCD as a result of their hearing
impairment, carrying out a BAER in dogs exhibiting FCS is deﬁnitely
recommended.
Different FC treatment protocols have been proposed in the litera-
ture. Trials using AEDs, including treatments with PB, primidone, diaze-
pam, mephobarbital, and diphenylhydantoin, showed no rewarding
results [2,6,12,13,15]. One case of a Bernese Mountain Dog (BMD)
with complex partial seizures combined with other neurological symp-
toms, including FC, was shown to periodically improve with huperzine
A treatment [12]. This drug is a compound isolated from Chinese club
moss with an NMDA receptor-blocking activity, anticholinesterase ac-
tivity, and anticonvulsant properties [35]. Phenobarbital was found to
be ineffective in the treatment of FCS in the CKCS [1,15]. The FCS was
suspected to be a form of OCD in the CKCS by Rusbridge, and a PB ther-
apy was proposed, followed by ADT (FLX or clomipramine) combined
with behavioral training, if the former was unsuccessful [15]. However,
to date, there is no speciﬁc therapeutic protocol involving this treatment
option. In humans, the use of SSRIs gives a high success rate in the treat-
ment of OCD [36]. In our study, the group treated with FLX responded
signiﬁcantly better to treatment compared with the dogs treated with
PB. Fluoxetine is a SSRI drug andwas shown to be effective in a random-
ized, controlled clinical trial in dogs with diagnosed OCD [20]. However,
one should remember that SSRI can also act to reduce seizure frequency,
and improvement using this drug does not eliminate the epileptic etiol-
ogy of the syndrome [37].
Two dogs (CKCS) also received GB, and one dog (GSH) received DZ
for a short period of time. These drugs alone did not reduce FC symp-
toms. Tricyclic antidepressants (clomipramine and amitriptyline)
were used in two cases with no effect, but a deﬁnitive assessment of
the usefulness of those drugs cannot be made.
Based on the retrospective analysis of 24 dogs and literature data, it
is advised to perform several diagnostic procedures in order to deter-
mine medical, neurological, and behavioral disorders that may cause
FCS (Table 1). We suggest carrying out EEG recordings in dogs
exhibiting FCS in order to evaluate EEG data in FCS more comprehen-
sively. If it is not possible to perform an EEG recording and based on
the ﬁndings of this study that PB seemed less effective at treating the
FC behavior than FLX, a 4- to 6-week trial of FLX at a dose of 1-mg/kg
BID treatment is recommended. If the animals have a concomitant his-
tory of seizures and FCS, routine epilepsy diagnostics and an adequate
therapy ought to be implemented.
4.1. Study limitations
A double blinded, placebo-controlled trial would be of more value in
assessing the usefulness of FLX in the therapy of FCS. However, the rare-
ness of this syndrome makes such a study extremely hard to perform.
5. Conclusion
The underlying cause is likely to vary among dogs with FCS. There-
fore, thorough diagnostic testing should be performed in order to ex-
clude any obvious CNS pathologies. However, it may be difﬁcult to
differentiate between OCD and epilepsy in many cases. Most of the
presented cases in this study showed satisfactory improvement with
FLX treatment.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yebeh.2015.10.013.
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